Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/1/2024 | $30.00 | Sector Outperform | Scotiabank |
| 9/25/2023 | $25.00 → $32.00 | Hold → Buy | Canaccord Genuity |
| 8/8/2023 | $30.00 | Market Perform → Outperform | SVB Securities |
| 5/23/2023 | $13.00 → $27.00 | Neutral → Buy | Goldman |
| 8/15/2022 | $40.00 → $12.00 | Buy → Hold | Canaccord Genuity |
| 8/9/2022 | $38.00 → $18.00 | Outperform → Market Perform | Cowen |
| 8/9/2022 | $35.00 → $15.00 | Outperform → Mkt Perform | SVB Leerink |
| 3/2/2022 | $85.00 → $60.00 | Overweight | JP Morgan |
4 - Quanterix Corp (0001503274) (Issuer)
4 - Quanterix Corp (0001503274) (Issuer)
4 - Quanterix Corp (0001503274) (Issuer)
Scotiabank initiated coverage of Quanterix with a rating of Sector Outperform and set a new price target of $30.00
Canaccord Genuity upgraded Quanterix from Hold to Buy and set a new price target of $32.00 from $25.00 previously
SVB Securities upgraded Quanterix from Market Perform to Outperform and set a new price target of $30.00
SC 13G/A - Quanterix Corp (0001503274) (Subject)
SC 13G - Quanterix Corp (0001503274) (Subject)
SC 13G/A - Quanterix Corp (0001503274) (Subject)
4 - Quanterix Corp (0001503274) (Issuer)
4 - Quanterix Corp (0001503274) (Issuer)
Sixth Consecutive Quarter of Double-Digit Growth Reaffirms Full Year 2024 Outlook Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced preliminary financial results for the third quarter ended September 30, 2024 and reaffirmed its full year 2024 guidance. The Company also disclosed the need to restate certain prior period financial statements to correct non-cash errors related to those periods. "Quanterix continues to build on our strong momentum, achieving our sixth consecutive quarter of double-digit growth. We are pleased to reaffirm our full year 2024 outlook, which is especially notable given the
Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Tuesday, November 12, 2024, at 4:30 p.m. E.T., to discuss third quarter 2024 financial results. Quanterix will issue a press release regarding third quarter 2024 financial results prior to the conference call on Tuesday, November 12, 2024, after the market closes. The press release will be posted on the Quanterix website at https://www.quanterix.com/. To pre-register for the conference call with a webcast link click here. For audio use the following dial-in number and passcode: USA & Canada - Toll-Free (800) 715-9871
Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the second quarter ended June 30, 2024. "Our research business once again delivered strong performance in the second quarter, growing double digits," said Masoud Toloue, Chief Executive Officer of Quanterix. "Demand for Simoa sensitivity continues, as highlighted by a 35% increase in Accelerator service revenue compared to the corresponding prior year period, as customers are able to access our technology without impacting their capital expenditure budgets. For the balance of 2024, we expect to continue to execute against our strate
SCHEDULE 13G - Quanterix Corp (0001503274) (Subject)
NT 10-Q - Quanterix Corp (0001503274) (Filer)
8-K - Quanterix Corp (0001503274) (Filer)
Sixth Consecutive Quarter of Double-Digit Growth Reaffirms Full Year 2024 Outlook Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced preliminary financial results for the third quarter ended September 30, 2024 and reaffirmed its full year 2024 guidance. The Company also disclosed the need to restate certain prior period financial statements to correct non-cash errors related to those periods. "Quanterix continues to build on our strong momentum, achieving our sixth consecutive quarter of double-digit growth. We are pleased to reaffirm our full year 2024 outlook, which is especially notable given the
Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Tuesday, November 12, 2024, at 4:30 p.m. E.T., to discuss third quarter 2024 financial results. Quanterix will issue a press release regarding third quarter 2024 financial results prior to the conference call on Tuesday, November 12, 2024, after the market closes. The press release will be posted on the Quanterix website at https://www.quanterix.com/. To pre-register for the conference call with a webcast link click here. For audio use the following dial-in number and passcode: USA & Canada - Toll-Free (800) 715-9871
LucentADTM Complete improves on single biomarker tests, significantly reducing the intermediate zone, providing results for more patients Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ:QTRX), has introduced LucentAD Complete, a new multi-marker blood test designed to help detect Alzheimer's Disease (AD) in a broader range of patients. Recent Alzheimer's Association criteria for diagnosing Alzheimer's recommend that plasma p-Tau 217 tests be designed with two cutoffs to confidently differentiate between patients with or without amyloid pathology, a hallmark of AD. However, this approach leaves an "intermediate zone" of uncertainty, requiring patients that fall into this zone
Goldman Sachs analyst Matthew Sykes maintains Quanterix (NASDAQ:QTRX) with a Buy and lowers the price target from $35 to $24.
Quanterix (NASDAQ:QTRX) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.33) by 21.21 percent. This is a 62.5 percent decrease over losses of $(0.16) per share from the same period last year. The company reported quarterly sales of $32.066 million which beat the analyst consensus estimate of $31.620 million by 1.41 percent. This is a 12.69 percent increase over sales of $28.456 million the same period last year.
Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced the appointment of Ivana Magovčević-Liebisch, Ph.D., J.D. to its Board of Directors. Dr. Magovčević-Liebisch brings more than 25 years of biopharmaceutical industry experience, including founding Vigil Neuroscience, Inc. four years ago, where she serves as President and Chief Executive Officer. Under her leadership, Vigil raised more than $350 million and advanced its lead pipeline candidates into clinical development, including the first clinical-stage small molecule TREM2 agonist for the potential treatment of Alzheimer's dis
Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultra-sensitive biomarker detection, today announced that it appointed Jeffrey Elliott to its Board of Directors. Mr. Elliott brings two decades of senior leadership experience in the medical diagnostics industry, including 8 years at Exact Sciences Corp., where he served as chief financial officer from November 2016 to May 2024 and chief operating officer from April 2021 to May 2023. While at Exact Sciences, he was responsible for finance, strategy and business development, helping to effectively scale the business, achieving high revenue growth during his tenure, and overseei
CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Karen Flynn as a new independent director to its Board. Ms. Flynn is an accomplished healthcare leader with over 35 years of commercial, operations and general management experience in the pharmaceutical services industry. She most recently served as Interim President of BioModalities at Catalent (NYSE:CTLT), a global provider of development and manufacturing solutions for drugs, biologics, cell and gene therapies and consumer heal